Less is more at NIBR. Narasimhan on the R&D makeover at Novartis

Restructuring the company was the first part of the Novartis turnaround that CEO Vas Narasimhan has been working on in his five years in the role. His sights are now set on bringing focus and discipline to R&D. How successful he is at that may dictate his legacy. 

In Part II of an interview with BioCentury, Narasimhan discussed the change in culture he and Fiona Marshall, president of BioMedical Research (formerly Novartis Institutes for BioMedical Research, or NIBR), have been creating since she took the helm of the company’s research arm on Nov. 1, 2022...